Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

• Váldodahkkit: Stefan Willmann (Dahkki), Ibrahim Ince (Dahkki), Maurice Ahsman (Dahkki), Katrin Coboeken (Dahkki), Yang Zhang (Dahkki), Kirstin Thelen (Dahkki), Dagmar Kubitza (Dahkki), Peter Zannikos (Dahkki), Wangda Zhou (Dahkki), Liza Miriam Pina (Dahkki), Teun Post (Dahkki), Jörg Lippert (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2022-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body weights <30 kg) with congenital heart disease...